Engineered mini livers by Sangeeta Bhatia as injection alternative

Professor Sangeeta Bhatia and colleagues have developed an injectable approach that delivers functioning hepatocytes inside hydrogel microspheres as a potential alternative to liver transplantation. The microspheres let packed cells flow through a syringe, then regain solid structure in the body, and the grafts remained viable in mice for at least two months.

How do the injected mini livers work?

The system mixes functioning hepatocytes with hydrogel microspheres that allow injection and then support local engraftment. The spheres act like a liquid when they are closely packed so they can be injected through a syringe, then regain their solid structure once inside the body. That local scaffold keeps cells together and accelerates their connection to nearby blood vessels, helping the hepatocytes generate many liver enzymes and proteins.

What evidence is there in animals?

Injected hepatocyte–microsphere grafts persisted and remained functional in mice for a minimum of two months. In the study the grafts were delivered into the fat tissue of the belly, where the researchers observed viable cells producing a range of liver proteins. Lead author Vardhman Kumar, an MIT postdoc, says, "These microspheres provide the hepatocytes with a niche where they can stay localized and become connected to the host circulation much faster." The team presents this survival and functional output in mice as the primary preclinical support for the technique.

Who might this help and how would it be used?

The approach targets people with chronic liver disease who are waiting for an organ transplant or are not strong enough for surgery. The researchers envision the grafts as both a non-surgical alternative and a bridge to transplantation, providing support until a donor organ becomes available. Patients would likely need immunosuppressive drugs, though the team is exploring methods to evade the immune system or to use the microspheres to deliver immunosuppressants locally.

Why it matters

Injectable hepatocyte grafts change the delivery constraints that make liver replacement highly invasive. If the microsphere approach scales and translates to humans, it could expand options for patients who cannot tolerate major surgery and reduce dependence on donor-organ timing. It also reframes cell therapy for the liver from isolated cell injection toward a localized, vessel-connected graft that performs multiple hepatic functions.

What to watch

Progress on immune compatibility and localized immunosuppression is the next critical signal: whether the group can get hepatocytes to evade the immune system or use the microspheres to deliver immunosuppressants locally. A demonstration of functionality beyond two months, alternate implant sites beyond belly fat, and preclinical data showing clinically meaningful restoration of liver functions would be the immediate milestones to follow.